NVAX

Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real question is whether Wall Street is pricing in a cancer breakthrough that has yet to prove itself outside one tumor type.

Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.

If you backed Novavax at the start of the year, the story looks very different now than it did on day one. For Novavax shareholders, the return from the start of the year was 36.0%, including dividends.

Novavax has had a volatile few years, and the share price history raises a straightforward question for you as an investor.

Over the past six months, Novavax has been a great trade, beating the S&P 500 by 17.7%. Its stock price has climbed to $10.87, representing a healthy 25.4% increase.

Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces.